Evelyne Yehudit Bischof, MD, MPH, FEFIM

Internal medicine

Chief physician associate of internal medicine and oncology at University Hospital Renji of Jiaotong University, Shanghai
Emergency medicine physician at the Shanghai East International Medical Center

Longevity

Executive concierge longevity physician EPO8 (Executive Performance Optimization 8), private practice
Longevity physician at Human Longevity Inc.

Longevity Science Foundation, Head of the Visionary Board

Advisory

Clinical longevity senior advisor at Insilico Medicine
Scientific Advisor at Maximon

Currently also affiliated with the International Center for Multimorbidity and Complexity in Medicine (ICMC), Universität Zürich, and prev. senior attending physician of internal medicine at the University Hospital Basel.

Swiss board certified as internal medicine specialist (FMH), trained in Europe, USA and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Tongji University hospitals, Shanghai and University Hospitals of Zurich and Basel (Switzerland).

Research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. EB published over 80 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc.

EB spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East Hospital. EB sits on several scientific and advisory boards of biotech and longevity hubs.